Skip to content
Clinical Trials – home

Portugal Clinical trials in Portugal – page 39

  • 355 / 824 trials open to patients
  • 20 research sites
  • 48 cities
PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
City
Type of trial
Recruitment status
Quick filters

824 trials in Portugal

Open in trial search

Breast cancer+1

Not recruiting

Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Novartis Pharma AG

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Cardiac amyloidosis

Not recruiting

Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Novo Nordisk A/S

Anxiety+1

Not recruiting

Comparison of Oxazepam 50 mg orodispersible tablets and Oxazepam 50 mg standard tablets in healthy volunteers to test if they work the same way in the body

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Oxazepam
  • Sponsor:Neuraxpharm Pharmaceuticals S.L.

Nicotine dependence

Not recruiting

Study of cytisinicline and moxifloxacin effects on heart electrical activity in healthy smokers with nicotine addiction

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Cytisinicline
  • Sponsor:Achieve Life Sciences Inc.

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Amgen Inc.

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Study of ABBV-CLS-628 to evaluate safety and effectiveness in adults with Autosomal Dominant Polycystic Kidney Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:ABBV-CLS-628
  • Sponsor:Calico Life Sciences LLC

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Cardiac amyloidosis

Not recruiting

Study on the Effects and Safety of Coramitug for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Top 10 cities in Portugal

Where most of the country's trials are run

No. 1 most studied

Lisbon

638trials · 29% of the top 10
research sites
3
View city
29%Lisbon

Shares are of these cities' trials together.

All cities with clinical trials

48 cities, A–Z – pick yours to filter the trials

Clinical research in Portugal

What the registry says about research in the country

01 Oncology and Cancer Research

Portugal is actively engaged in clinical trials across a broad spectrum of oncological conditions. Research focuses on both solid tumors and hematological malignancies, with significant attention to non-small cell lung cancer, breast cancer, and various forms of lymphoma. Trials investigate novel immunotherapies, targeted therapies, and combination treatment regimens aimed at improving survival outcomes and quality of life for patients with advanced or metastatic disease.

  • Advanced melanoma and metastatic solid tumors with specific genetic mutations
  • HER2-positive and HER2-negative breast cancer across various disease stages
  • Multiple myeloma, including newly diagnosed and relapsed/refractory cases
  • Colorectal cancer, gastric adenocarcinoma, and hepatocellular carcinoma

The research landscape emphasizes precision medicine approaches, evaluating therapies based on biomarker expression and genomic alterations. Studies explore both first-line treatments and options for patients who have progressed on standard therapies, reflecting the comprehensive nature of cancer care development in the country.

02 Autoimmune and Inflammatory Diseases

A substantial portion of clinical research in Portugal addresses autoimmune disorders and chronic inflammatory conditions. Trials examine novel therapeutic agents for rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The focus extends to understanding disease mechanisms and developing targeted interventions that modulate immune responses.

  • Systemic lupus erythematosus and lupus nephritis treatment strategies
  • Crohn's disease and ulcerative colitis management in adult and pediatric populations
  • Psoriatic arthritis, ankylosing spondylitis, and other spondyloarthropathies
  • Sjögren's syndrome and systemic sclerosis therapeutic approaches

Research efforts prioritize both induction and maintenance therapies, with particular attention to achieving clinical remission and improving long-term disease control. Studies also evaluate the safety and efficacy of biological agents and small molecule inhibitors in diverse patient populations.

03 Cardiovascular Disease Research

Clinical trials addressing cardiovascular conditions represent a significant area of medical research in Portugal. Studies focus on heart failure, atrial fibrillation, acute coronary syndromes, and prevention of cardiovascular events in high-risk populations. Research encompasses both acute interventions and long-term management strategies aimed at reducing morbidity and mortality.

  • Heart failure with reduced, mildly reduced, and preserved ejection fraction
  • Prevention of stroke and systemic embolism in atrial fibrillation patients
  • Acute myocardial infarction treatment and secondary prevention
  • Hypertrophic cardiomyopathy and transthyretin amyloid cardiomyopathy

Investigations include novel anticoagulants, antiplatelet agents, and therapies targeting specific cardiac pathologies. The research also addresses atherosclerotic cardiovascular disease in patients with metabolic comorbidities and chronic kidney disease.

04 Neurological and Neurodegenerative Disorders

Portugal participates in extensive research on neurological conditions, with particular emphasis on multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Trials evaluate disease-modifying therapies, symptomatic treatments, and interventions aimed at slowing disease progression. Studies also address rare neurological conditions and epileptic disorders.

  • Relapsing-remitting and progressive forms of multiple sclerosis
  • Early and established Alzheimer's disease, including cognitive decline prevention
  • Parkinson's disease motor and non-motor symptom management
  • Epileptic encephalopathies including Dravet syndrome and Lennox-Gastaut syndrome

Research initiatives explore novel mechanisms of action, including immunomodulatory approaches and therapies targeting neuroinflammation. Trials also investigate treatments for frontotemporal dementia, amyotrophic lateral sclerosis, and other progressive neurological conditions.

05 Respiratory Diseases and Pulmonary Conditions

Clinical trials focusing on respiratory tract diseases address conditions ranging from chronic obstructive pulmonary disease to interstitial lung diseases. Research evaluates treatments for asthma, cystic fibrosis, and pulmonary arterial hypertension, with emphasis on improving lung function and quality of life for patients with chronic respiratory conditions.

  • Idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases
  • Severe asthma with eosinophilic phenotype
  • Cystic fibrosis in patients with various CFTR mutations
  • Pulmonary arterial hypertension in adult and pediatric populations

Studies investigate both anti-inflammatory therapies and disease-modifying agents, including novel formulations and delivery methods. Research also addresses bronchiectasis and respiratory complications in patients with underlying systemic conditions.

06 Metabolic and Endocrine Disorders

Portugal contributes to research on metabolic diseases and endocrine disorders, with significant focus on type 2 diabetes, obesity, and related cardiovascular complications. Trials evaluate therapies for non-alcoholic steatohepatitis, hypertriglyceridemia, and rare metabolic conditions. The research emphasizes integrated approaches addressing multiple aspects of metabolic syndrome.

  • Type 2 diabetes management and cardiovascular risk reduction
  • Non-alcoholic steatohepatitis and fatty liver disease progression
  • Obesity treatment in patients with atherosclerotic cardiovascular disease
  • Familial hypercholesterolemia and severe hypertriglyceridemia

Studies explore novel therapeutic agents including GLP-1 receptor agonists and combination therapies targeting multiple metabolic pathways. Research also addresses endocrine conditions such as hypoparathyroidism and congenital adrenal hyperplasia.

07 Renal and Kidney Diseases

Clinical research addressing kidney diseases encompasses both acute and chronic conditions. Trials focus on chronic kidney disease, IgA nephropathy, and complications such as secondary hyperparathyroidism. Research evaluates interventions to slow disease progression, manage complications, and improve outcomes for patients requiring dialysis or transplantation.

  • IgA nephropathy and focal segmental glomerulosclerosis
  • Chronic kidney disease with proteinuria in adult and pediatric patients
  • Autosomal dominant polycystic kidney disease
  • Delayed graft function after kidney transplantation

Studies investigate therapies targeting inflammation, fibrosis, and immune-mediated kidney damage. Research also addresses the management of hyperkalemia and anemia associated with chronic kidney disease.

08 Dermatological Conditions

Portugal participates in trials addressing various skin diseases, with particular focus on atopic dermatitis, psoriasis, and hidradenitis suppurativa. Research evaluates both systemic and topical therapies aimed at controlling inflammation, reducing symptoms, and improving skin appearance. Studies also address rare genetic skin conditions and immune-mediated dermatoses.

  • Moderate to severe atopic dermatitis in adult and pediatric populations
  • Chronic plaque psoriasis and associated comorbidities
  • Hidradenitis suppurativa management and quality of life improvement
  • Vitiligo, alopecia areata, and cutaneous lupus erythematosus

Research emphasizes targeted immunomodulatory therapies and novel treatment approaches for conditions with significant impact on quality of life. Trials also investigate treatments for prurigo nodularis, chronic spontaneous urticaria, and rare blistering disorders.

09 Hematological Disorders

Clinical trials in hematology address both malignant and non-malignant blood disorders. Research focuses on acute myeloid leukemia, chronic lymphocytic leukemia, various lymphomas, and non-malignant conditions such as immune thrombocytopenia and hemophilia. Studies evaluate novel cellular therapies, targeted agents, and supportive care interventions.

  • Acute lymphoblastic leukemia and acute myeloid leukemia treatment strategies
  • Follicular lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma
  • Immune thrombocytopenia and chemotherapy-induced thrombocytopenia
  • Hemophilia A and B with and without inhibitors

Research includes investigations of CAR-T cell therapies, bispecific antibodies, and novel combinations of established agents. Trials also address myelofibrosis, polycythemia vera, and other myeloproliferative neoplasms.

10 Ophthalmological Research

Portugal contributes to clinical research on eye diseases, particularly conditions affecting the retina and macula. Trials evaluate treatments for age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Research aims to preserve and improve vision while reducing treatment burden for patients with chronic ocular conditions.

  • Neovascular age-related macular degeneration and geographic atrophy
  • Diabetic macular edema and diabetic retinopathy
  • Macular edema secondary to retinal vein occlusion
  • Uveitic macular edema and other inflammatory eye conditions

Studies investigate novel anti-VEGF agents, extended dosing regimens, and combination therapies. Research also addresses retinopathy of prematurity and rare genetic eye diseases affecting pediatric populations.

11 Rare and Genetic Disorders

Clinical trials in Portugal address numerous rare diseases and genetic conditions, reflecting a commitment to advancing treatments for underserved patient populations. Research encompasses lysosomal storage disorders, metabolic diseases, and rare forms of muscular dystrophy and connective tissue disorders.

  • Fabry disease, Gaucher disease, and other lysosomal storage disorders
  • Achondroplasia, hypochondroplasia, and skeletal dysplasias
  • Spinal muscular atrophy and neuromuscular disorders
  • Epidermolysis bullosa and rare skin fragility syndromes

Studies evaluate enzyme replacement therapies, gene therapies, and novel approaches to managing disease manifestations. Research also addresses hereditary angioedema, alpha-1 antitrypsin deficiency, and rare forms of amyloidosis.

12 Infectious Diseases

Portugal participates in research addressing various infectious diseases, including bacterial infections, viral diseases, and emerging pathogens. Trials evaluate novel antimicrobial agents, antiviral therapies, and preventive strategies. Research also addresses complications of infections and long-term sequelae.

  • Acute bacterial skin and skin structure infections
  • Ventilator-associated pneumonia and community-acquired pneumonia
  • HIV-1 infection treatment and prevention strategies
  • COVID-19 and emerging viral infections

Studies investigate both treatment and prevention approaches, including vaccine development and immunomodulatory therapies. Research also addresses Clostridioides difficile infection and management of infections in immunocompromised patients.

13 Gastroenterological Disorders

Clinical research on digestive system diseases encompasses conditions affecting the entire gastrointestinal tract. Beyond inflammatory bowel diseases, trials address gastroesophageal reflux disease, eosinophilic esophagitis, and functional gastrointestinal disorders. Research evaluates both pharmacological interventions and procedural approaches.

  • Eosinophilic esophagitis in adult and pediatric populations
  • Erosive esophagitis and gastroesophageal reflux complications
  • Irritable bowel syndrome and functional gastrointestinal disorders
  • Prevention of esophageal strictures after endoscopic procedures

Studies investigate novel anti-inflammatory agents, prokinetic therapies, and approaches to managing chronic symptoms. Research also addresses complications of gastrointestinal diseases and quality of life improvements.

14 Musculoskeletal and Rheumatic Conditions

Portugal engages in research on musculoskeletal diseases beyond traditional rheumatological conditions. Trials address osteoarthritis, tendinopathies, and rare bone disorders. Research evaluates interventions for pain management, functional improvement, and disease modification in conditions affecting bones, joints, and connective tissues.

  • Erosive osteoarthritis of the hands and other joint disorders
  • Rotator cuff tendinopathy and lateral epicondylitis
  • Osteogenesis imperfecta and other genetic bone diseases
  • Fibrodysplasia ossificans progressiva and rare ossification disorders

Studies explore regenerative therapies, targeted biologics, and novel approaches to managing chronic pain and disability. Research also addresses pediatric musculoskeletal conditions and growth disorders.

15 Psychiatric and Behavioral Health

Clinical trials addressing mental health conditions focus on major depressive disorder, schizophrenia, and obsessive-compulsive disorder. Research evaluates novel therapeutic approaches for treatment-resistant conditions and investigates interventions for specific symptom clusters. Studies also address behavioral manifestations of neurodegenerative diseases.

  • Major depressive disorder with insomnia symptoms
  • Schizophrenia symptom management and functional outcomes
  • Obsessive-compulsive disorder treatment approaches
  • Agitation and psychosis associated with Alzheimer's disease

Research emphasizes both pharmacological and non-pharmacological interventions, with attention to improving quality of life and functional capacity. Trials also investigate treatments for nicotine addiction and behavioral symptoms in dementia.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.